The Cartherics and Zucker Institute collaboration one to watch! Using an iPSC-derived CAR-NK platform against tissue factor, for endometriosis as well as solid tumours, is a genuinely different mechanism to anything currently offered to patients, from what I've read... Keeping the stage in view though: it is a research collaboration and option agreement rather than anything approaching a trial in people yet!
Including part-time and seasonal workers regardless of insurance status makes the MiSalud example unusually useful. It tests whether an employer benefit can reach people who are often left outside premium health programmes.
The Cartherics and Zucker Institute collaboration one to watch! Using an iPSC-derived CAR-NK platform against tissue factor, for endometriosis as well as solid tumours, is a genuinely different mechanism to anything currently offered to patients, from what I've read... Keeping the stage in view though: it is a research collaboration and option agreement rather than anything approaching a trial in people yet!
This is a useful clarification! It’s an early - but exciting - signal for sure of what might be possible
Including part-time and seasonal workers regardless of insurance status makes the MiSalud example unusually useful. It tests whether an employer benefit can reach people who are often left outside premium health programmes.